1. Home
  2. BNGO vs HOTH Comparison

BNGO vs HOTH Comparison

Compare BNGO & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.30

Market Cap

14.3M

Sector

Industrials

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$0.66

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
HOTH
Founded
2003
2017
Country
United States
United States
Employees
N/A
3
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
12.8M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
BNGO
HOTH
Price
$1.30
$0.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$5.00
AVG Volume (30 Days)
120.5K
3.0M
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
94.50
29.69
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
$14.99
N/A
Revenue Next Year
$34.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$0.49
52 Week High
$5.50
$2.12

Technical Indicators

Market Signals
Indicator
BNGO
HOTH
Relative Strength Index (RSI) 56.35 40.19
Support Level $1.09 $0.49
Resistance Level $1.33 $0.80
Average True Range (ATR) 0.06 0.05
MACD 0.01 -0.00
Stochastic Oscillator 56.55 3.25

Price Performance

Historical Comparison
BNGO
HOTH

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Share on Social Networks: